CNSP

CNS Pharmaceuticals, Inc. (CNSP) ESG Analysis Analysis (2026)

Invetso Score: 5.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

Limited disclosed environmental intensity metrics constrain peer benchmarking, leaving CNSP neither clearly advantaged nor clearly lagging versus similarly small-cap peers.

The absence of reported R&D-to-revenue spending in the provided metrics limits evidence of product or process innovation that could reduce environmental footprint relative to peers.

Zero gross profit margin in the supplied data suggests limited operating scale to fund environmental programs, which typically leaves CNSP behind better-resourced peers.

No material environmental controversies or regulatory breaches were provided, so the company appears broadly neutral rather than structurally weaker on environmental exposure versus peers.

Social

Score:

The provided metrics do not disclose workforce, safety, or customer-impact indicators, which makes CNSP's social positioning difficult to distinguish from peers.

Zero stock-based compensation to revenue may indicate limited equity-based retention tools, potentially constraining talent alignment relative to peers with stronger incentive structures.

The absence of reported social KPIs prevents evidence of stronger labor, diversity, or community practices that would support a peer advantage.

No major social controversies were provided, but the lack of transparent social disclosure keeps CNSP at a middling relative position versus peers.

Governance

Score:

Net debt to EBITDA of 1.2x suggests moderate balance-sheet discipline, which is generally more favorable than highly levered peers from a governance-risk perspective.

Zero debt-to-equity in the supplied data indicates limited leverage complexity, reducing creditor pressure and governance strain relative to more indebted peers.

The absence of stock-based compensation in the metrics may limit dilution concerns, but it also provides little evidence of a robust long-term incentive framework versus peers.

No filing-based governance red flags or control controversies were provided, so CNSP appears broadly average rather than clearly advantaged on governance.

Overall Score

Score:

CNSP appears broadly average versus peers across ESG dimensions, with limited disclosed data and no clear structural advantage or major controversy driving relative positioning.

Score Driver: Sparse ESG Disclosure Limits Evidence Of A Peer-Leading Position.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on CNS Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →